Form 4: Rhythm Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, sold shares of common stock on February 12, 2025, to cover withholding taxes related to vesting restricted stock units.

Summary

• On February 12, 2025, Joseph Shulman, the Chief Technical Officer of Rhythm Pharmaceuticals, sold 462 shares of common stock at $56.39 per share and 7 shares at $57.09 per share.
• The sales were executed under a pre-existing Rule 10b5-1 trading plan adopted before February 27, 2023.
• The purpose of the sales was solely to cover withholding taxes associated with the vesting of previously reported restricted stock units.
• Following the transactions, Shulman directly owns 5,612 shares of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax purposes) by an executive, which is neither particularly positive nor negative.

Industry Context

Executive stock sales are a common occurrence, particularly to cover tax obligations related to equity compensation. The use of a 10b5-1 plan indicates the sales were pre-planned and not based on insider information at the time of the transaction.

Stakeholder Impact

• The stock sale is unlikely to have a significant impact on shareholders, as it was a relatively small transaction executed under a pre-existing trading plan.

Key Dates